Information Provided By:
Fly News Breaks for April 13, 2015
CLVS
Apr 13, 2015 | 06:43 EDT
Goldman upgraded Clovis to Buy with a $117 price target, up from $68. The firm increased its adjusted peak sales estimate to $2B from $1.5B for Rociletinib, a lung cancer drug, and sees a greater probability of M&A.
News For CLVS From the Last 2 Days
There are no results for your query CLVS